Gufic Biosciences Approves Q3 Results and Plans Entry into Philippine Market via Subsidiary
Gufic Biosciences Limited, in a strategic move announced on August 14, 2026, confirmed the results of its Board of Directors meeting. The board considered and approved the unaudited financial performance for the quarter ending June 30, 2026, while simultaneously endorsing plans to establish a subsidiary in the Philippines.The company's operational focus remains within the Pharmaceuticals sector. The management reviewed the quarterly results, which reflect consolidated and standalone figures.
Financial Highlights for Q Ended June 30, 2026
Based on the unaudited statements for the quarter ended June 30, 2026, key financial performance indicators are as follows:| Metric | Value (in Lakhs) |
|---|---|
| Revenue from Operations | 26,081.80 |
| Total Income | 26,127.55 |
| Net Profit from Continuing Operations | 2,231.28 |
| Total Comprehensive Income | 2,238.81 |
Strategic Expansion into the Philippines Market
A key outcome of the board meeting was the approval for the incorporation and investment in a new entity in the Philippines. This strategic move aims to expand Gufic Biosciences’ footprint in Southeast Asia.The proposed subsidiary, which may be named Gufic Philippines Inc., will operate within the pharmaceutical industry. Its primary function will involve marketing, sale, and distribution of the Company's pharmaceutical products across the Philippines. The entity will also be responsible for holding and managing Intellectual Property Rights within the region.
Gufic Biosciences Limited is set to invest through a cash subscription to the equity share capital of this new subsidiary. The investment amount is estimated at up to USD 250,000 or its equivalent in Philippine Peso. The Company intends to maintain control over the proposed subsidiary and aims for approximately 99.99% of the equity share capital.
GUFICBIO Stock Price Movement
Shares of Gufic Biosciences Limited slipped by 2.27% on Friday, closing at ₹422.20 as the pharmaceutical stock finished lower. The equity traded a total volume of 165,948 shares during the session.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.